IMAGE: 68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any… view more
Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter…
PHILADELPHIA – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), researchers reported on a phase II prospective trial. Using gallium-68 (68Ga)-PSMA11 positron emission tomography (PET) imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.
Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to
Article originally posted at